Published date: Mar 10 2019

Journal Title: KnE Life Sciences

Issue title: The UGM Annual Scientific Conference Life Sciences 2016

Pages: 56–66

DOI: 10.18502/kls.v4i11.3852

P Nuringnuring_nw@yahoo.co.id

N Khairun

W Shofwal

A 32 yr old woman came to the hospital with a history of treatment for primary amenorrhea once in 2007. Diagnosis of Kallmann syndrome was made based on her complaint of amenorrhea and anosmia. Physical examination revealed abnormal growth of secondary sexual characteristic including undeveloped breasts, lack of armpit and pubic hair. The external genitalia examination showed very slightly pubic hair, a small labia minora, and vagina (± 0.5 cm diameter, 5 cm depth). The abdominal ultrasound examination showed a small uterus. Bone marrow densitometry examination denoted osteoporosis in L1, L2, L3, L4 vertebrae and pelvic bone. Chromosomal examination showed the karyotype of 46 XX. The olfactory test resulted in anosmia. Kallmann syndrome is a developmental disorder which consists of a combination of hypogonadotropic-hypogonadism and anosmia. The characteristics of patients diagnosed with Kallmann syndrome were delayed puberty and anosmia. A chromosomal and hormonal examination might be performed to rule out Klinefelter
and Turner syndrome. Magnetic Resonance Imaging (MRI) examination was useful to determine whether there was any olfactory bulb or pituitary gland and hypothalamus disorder. Patient’s management included hormone replacement therapy and fertility therapy to maintain healthy hormone circulation equal to a normal physiological value according to patients’ ages. In this case, the effect of the drugs was to build a temporary endometrial wall. Once the pills are stopped, the patient will not undergo her menstruation phase anymore because of her pituitary hormone production is inadequate. This medication also gave more strength to bones due to her osteoporosis.

Keywords: Amenorrhea, Anosmia, Genetic disorder, Hypogonadismhypogonadotropic, Kallmann syndrome.

[1] Dode C, Pierre H. Kallmann syndrome. European journal of Human Genetics 2009;17:139–146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2986064/


[2] Castaynera-Perdomo A, Castaynera-Ruiz L, González-Marrero I, Castañeyra-Ruiz A, Gonzalez-Toledo JM, Castañeyra-Ruiz M, Carmona-Calero EM. Early treatment of Kallmann syndrome may prevent eunuchoid appearance and behavior. Medical Hypotheses 2014;82:74–76. https://www.ncbi.nlm.nih.gov/pubmed/24296236


[3] Meczekalski B, Podfiguma-Stopa A, Smolarczyk R, Smolarczyk R, Katulski K, Genazzani AR. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecological Endocrinology 2013;29(4):296–300. https://www.ncbi.nlm. nih.gov/pubmed/23368665


[4] Kim SH. Congenital hypogonadotropic hypogonadism and kallmann syndrome: Past, present and future. Endocrinology and Metabolism 2015;30(4):456–466. https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4722398/


[5] Arkoncel MLCR, Arkoncel FRP, Lantion-Ang FL. A case of kallmann syndrome. BMJ Case Reports 2011;2011: bcr0120113727. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3070321/


[6] Forni PE, Wray S. GnRH, anosmia and hypogonadotropic-hypogonadism: Where are we?. Front Neuroendocrinology 2015; 36:165–177 https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3070321/


[7] Ogata T, Fujiwara I, Ogawa E, Sato N, Udaka T, Kosaki K. Kallman syndrome phenotype in a female patient with CHARGE syndrome and CHD7 mutation. Endocr J., 2006;53:741–743. https://www.jstage.jst.go.jp/article/endocrj/53/6/ 53_6_741/_pdf/-char/en


[8] Leroy C, Fouveaut C, Leclerq S, Jacquemont S, Boullay HD, Lespinasse J, Delpech M, et al. Biallelic mutation in the prokineticin-2 gene in two sporadic cases of Kallmann syndrome. European Journal of Human Genetics 2008;16(7):865–868. https://www. ncbi.nlm.nih.gov/pubmed/18285834


[9] Melmed S. Fertility and fragrance: another cause of Kallmann syndrome. The Journal of Clinical Investigation 2015;125(6):2275–2278. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4497770/


[10] Tsai PS, Gill J. Mechanisms of disease: Insights into x-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab. 2006;2(3):160–171. https:// www.ncbi.nlm.nih.gov/pubmed/16932275


[11] Dode C, Teixetra L, Levillers, Fouveaut C, Bouchard P, Kottler ML, Lespinasse J, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. Plos Genetics 2006;2:1648–1652. http://journals.plos.org/plosgenetics/ article?id=10.1371/journal.pgen.0020175


[12] Chan YM, Guillebon A, Lang-Muritano M, Plummer L, Cerrato F, Tsiaras S, Gaspert S, et al. GnRH 1 mutation in patients with idiopathic hypogonadotropic-hypogonadisme. Pro Natl Sci USA 2006;106(28):11703–11708. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2710623/


[13] Massin N, Pêcheux C, Eloit C, Bensimon JL, Galey J, Kuttenn F, Hardelin JP, et al. X-chromosome-linked Kallmann syndrome: Clinical heterogenitty in three siblings carrying an intragenic deletion of the KAL-1 gene. J Clin Endocrinol Metab. 2003; 88(5):2003–2008. https://www.ncbi.nlm.nih.gov/pubmed/12727945